PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16845490-13	2006	On the other hand, SP600125 caused 85% inhibition of c-Fos induction by ACTH(39) and, in addition, ACTH(39) promotes JNK1/2 phosphorylation, suggesting that JNK is a major signaling pathway mediating c-Fos induction by ACTH(39) in these cells.	pyrazolanthrone	19-27	FBJ osteosarcoma oncogene	Mus musculus	53-58	
16845490-13	2006	On the other hand, SP600125 caused 85% inhibition of c-Fos induction by ACTH(39) and, in addition, ACTH(39) promotes JNK1/2 phosphorylation, suggesting that JNK is a major signaling pathway mediating c-Fos induction by ACTH(39) in these cells.	pyrazolanthrone	19-27	FBJ osteosarcoma oncogene	Mus musculus	200-205	
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	FBJ osteosarcoma oncogene	Mus musculus	112-117	
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	pyrazolanthrone	217-225	FBJ osteosarcoma oncogene	Mus musculus	26-31	
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	FBJ osteosarcoma oncogene	Mus musculus	147-152